Market revenue in 2023 | USD 171.0 million |
Market revenue in 2030 | USD 400.3 million |
Growth rate | 12.9% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.97% in 2023. Horizon Databook has segmented the Latin America hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
The Latin America hereditary angioedema therapeutics market exhibited significant growth in the past few years owing to high disease burden and increased demand for HAE drugs. Mexico, Brazil, and Argentina are prominent countries in the region, with Argentina having the highest percentage of diagnosed patients in Latin America.
Favorable government initiatives and research collaborations are anticipated to contribute to the market growth. In addition, the demand for drugs increased owing to current disease burden and high demand from healthcare providers.
Moreover, increasing R&D activities, coupled with rapid technological advancements in the region, are anticipated to fuel the market. Increasing government spending, growing investments by major pharmaceutical & biopharmaceutical companies, and the presence of major academic research institutes are factors likely to promote market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America hereditary angioedema therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account